Taina T Nieminen1,2, Christopher J Walker1, Alisa Olkinuora2, Luke K Genutis1, Margaret O'Malley3,4, Paul E Wakely5, Lisa LaGuardia3,4, Laura Koskenvuo6, Johanna Arola7, Anna H Lepistö6, Pamela Brock8, Ayse Selen Yilmaz9, Ann-Kathrin Eisfeld1, James M Church3,4, Päivi Peltomäki2, Albert de la Chapelle1. 1. Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 2. Department of Medical and Clinical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. 3. Department of Colorectal Surgery, Cleveland Clinical, Lakewood, Ohio. 4. Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Lakewood, Ohio. 5. Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio. 6. Department of Gastrointestinal Surgery, Abdominal Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 7. Department of Pathology, HUSLAB, University of Helsinki, Helsinki, Finland. 8. Division of Human Genetics, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio. 9. Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Abstract
Background: Familial adenomatous polyposis (FAP) is a condition typically caused by pathogenic germline mutations in the APC gene. In addition to colon polyps, individuals with FAP have a substantially increased risk of developing papillary thyroid cancer (PTC). Little is known about the events underlying this association, and the prevalence of somatic "second-hit" mutations in APC is controversial. Methods: Whole-genome sequencing was performed on paired thyroid tumor and normal DNA from 12 FAP patients who developed PTC. Somatic mutation profiles were compared with clinical characteristics and previously sequenced sporadic PTC cases. Germline variant profiling was performed to assess the prevalence of variants in genes previously shown to have a role in PTC predisposition. Results: All 12 patients harbored germline mutations in APC, consistent with FAP. Seven patients also had somatic mutations in APC, and seven patients harbored somatic mutations in KMT2D, which encodes a lysine methyl transferase. Mutation of these genes is extremely rare in sporadic PTCs. Notably, only two of the tumors harbored the somatic BRAF p.V600E mutation, which is the most common driver mutation found in sporadic PTCs. Six tumors displayed a cribriform-morular variant of PTC (PTC-CMV) histology, and all six had somatic mutations in APC. Additionally, nine FAP-PTC patients had rare germline variants in genes that were previously associated with thyroid carcinoma. Conclusions: Our data indicate that FAP-associated PTCs typically have distinct mutations compared with sporadic PTCs. Roughly half of the thyroid cancers that arise in FAP patients have somatic "second-hits" in APC, which is associated with PTC-CMV histology. Somatic BRAF p.V600E variants also occur in some FAP patients, a novel finding. We speculate that in carriers of heterozygous pathogenic mutations of tumor suppressor genes such as APC, a cooperating second-hit somatic variant may occur in a different gene such as KTM2D or BRAF, leading to differences in phenotypes. The role of germline variance in genes other than APC (9 of the 12 patients in this series) needs further research.
Background: Familial adenomatous polyposis (FAP) is a condition typically caused by pathogenic germline mutations in the APC gene. In addition to colon polyps, individuals with FAP have a substantially increased risk of developing papillary thyroid cancer (PTC). Little is known about the events underlying this association, and the prevalence of somatic "second-hit" mutations in APC is controversial. Methods: Whole-genome sequencing was performed on paired thyroid tumor and normal DNA from 12 FAPpatients who developed PTC. Somatic mutation profiles were compared with clinical characteristics and previously sequenced sporadic PTC cases. Germline variant profiling was performed to assess the prevalence of variants in genes previously shown to have a role in PTC predisposition. Results: All 12 patients harbored germline mutations in APC, consistent with FAP. Seven patients also had somatic mutations in APC, and seven patients harbored somatic mutations in KMT2D, which encodes a lysine methyl transferase. Mutation of these genes is extremely rare in sporadic PTCs. Notably, only two of the tumors harbored the somatic BRAF p.V600E mutation, which is the most common driver mutation found in sporadic PTCs. Six tumors displayed a cribriform-morular variant of PTC (PTC-CMV) histology, and all six had somatic mutations in APC. Additionally, nine FAP-PTCpatients had rare germline variants in genes that were previously associated with thyroid carcinoma. Conclusions: Our data indicate that FAP-associated PTCs typically have distinct mutations compared with sporadic PTCs. Roughly half of the thyroid cancers that arise in FAPpatients have somatic "second-hits" in APC, which is associated with PTC-CMV histology. Somatic BRAF p.V600E variants also occur in some FAPpatients, a novel finding. We speculate that in carriers of heterozygous pathogenic mutations of tumor suppressor genes such as APC, a cooperating second-hit somatic variant may occur in a different gene such as KTM2D or BRAF, leading to differences in phenotypes. The role of germline variance in genes other than APC (9 of the 12 patients in this series) needs further research.
Authors: Shahrun Niza Abdullah Suhaimi; Nadzrin Nazri; Mat Latar Nani Harlina; Nurismah Md Isa; Rohaizak Muhammad Journal: Malays J Med Sci Date: 2015 Jul-Aug
Authors: Cristina Albuquerque; Cor Breukel; Rob van der Luijt; Paulo Fidalgo; Pedro Lage; Frederik J M Slors; C Nobre Leitão; Riccardo Fodde; Ron Smits Journal: Hum Mol Genet Date: 2002-06-15 Impact factor: 6.150
Authors: Yanqiang Wang; Sandya Liyanarachchi; Katherine E Miller; Taina T Nieminen; Daniel F Comiskey; Wei Li; Pamela Brock; David E Symer; Keiko Akagi; Katherine E DeLap; Huiling He; Daniel C Koboldt; Albert de la Chapelle Journal: Thyroid Date: 2019-05-13 Impact factor: 6.568
Authors: Kimberly M Dalal; Dimitrios Moraitis; Carlos Iwamoto; Ashok R Shaha; Snehal G Patel; Ronald A Ghossein Journal: Head Neck Date: 2006-05 Impact factor: 3.147
Authors: Jae-Hui Kim; Ji Yun Jeong; An Na Seo; Nora Jee-Young Park; Moonsik Kim; Ji Young Park Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Yun Yu; Freek Manders; Guy C M Grinwis; Martien A M Groenen; Richard P M A Crooijmans Journal: BMC Genomics Date: 2022-09-23 Impact factor: 4.547
Authors: Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti Journal: Endocr Connect Date: 2022-01-31 Impact factor: 3.335